Table 1.
Patient characteristics
| Age | Sex | # prior Rx |
FISH | Baseline B2M |
IGHV MS |
Largest lymph node pre- treatment (cm) |
Rai stage |
Infection | Response | Progression | CD4+PD1+ T cells [%] |
CD8+PD1+ T cells [%] |
CD19+ CD5+PD1+ [%] |
CD19+ CD5+PDL1+ [%] |
CD19+CD5+ p-S727-STAT3 [MFI] |
IgG | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pre | 3mo | 6mo | pre | 3mo | 6mo | pre | 3mo | 6mo | pre | 3mo | 6mo | pre | 3mo | 6mo | pre | |||||||||||
| 55 | F | 1 | Del(17p) | 2.5 | NR | 2.9 | 4 | PR | 38.0 | 27.5 | NA | 26.4 | 13.9 | NA | 64.6 | 11.9 | NA | 22 | 25.8 | NA | 992 | 358 | 381 | 566 | ||
| 57 | M | 1 | Del(11q) | 3.5 | NR | 6.3 | 3 | PR | 45.9 | 44.1 | NA | 13.9 | 9.7 | NA | 31.7 | 42.5 | NA | 34.1 | 15.7 | NA | NA | NA | NA | 692 | ||
| 59 | F | 3 | Del(17p) | 3.8 | UM | 5.5 | 4 | CR | 27.2 | 14.5 | NA | 21.3 | 10.1 | NA | 39.2 | 3.3 | NA | 12.4 | 5 | NA | 375 | NA | 180 | 383 | ||
| 60 | M | 1 | Del(11q) | 2.6 | UM | 3.6 | 1 | PR | 31.2 | NA | 24.1 | 30.3 | NA | 21.8 | 54.1 | NA | 1 | 8.5 | NA | 19.3 | NA | NA | NA | 521 | ||
| 63 | M | 2 | Del(17p) | 4.4 | MUT | 7.9 | 1 | PR | 40.7 | 43.6 | NA | 28.3 | 30.9 | 15.5 | 1.2 | NA | 6.6 | 6.8 | NA | 256 | 214 | NA | 417 | |||
| 64 | M | 0 | Del(17p) | 14.0 | UM | 9.1 | 3 | URI Grade 2 | PR | 42.0 | 40.6 | 40.9 | 19.8 | 20.5 | 15.8 | 8.4 | 0.7 | 0.6 | 18 | 9.7 | 8.1 | NA | NA | NA | 2380* | |
| 64 | F | 6 | Del(11q) | 9.3 | MUT | 2.8 | 4 | PR | 78.5 | 54.7 | 49.6 | 35.8 | 6.2 | 6.5 | 3.9 | 2.8 | 1.5 | 5.8 | 11.5 | 5.5 | 528 | 217 | 199 | 60 | ||
| 68 | M | 2 | Del(17p) | 6.3 | UM | 5.4 | 4 | PR | 17.6 | 15.8 | 15.8 | 15.0 | 9.9 | 12.7 | 6.9 | 1.5 | 3.3 | 9.8 | 6.2 | 8.2 | 322 | 119 | 172 | 444 | ||
| 68 | M | 1 | Del(17p) | 4.9 | UM | 5.4 | 2 | PR | 11m | 19.1 | 13.2 | NA | 17.1 | 9.4 | NA | 10.6 | 0.3 | NA | 51.3 | 54.4 | NA | NA | NA | NA | 369 | |
| 70 | M | 2 | Neg | 4.5 | UM | 3.4 | 1 | PR | 25.4 | 20.9 | NA | 19.8 | 7.3 | NA | 24.2 | 4.1 | NA | 16.5 | 14.6 | NA | NA | NA | NA | 567 | ||
| 71 | F | 3 | Trisomy 12 | 5.1 | UM | 3.0 | 4 | Cryptococcal meningitis Grade 4 | PR | 54.4 | 40.5 | 36.5 | 8.6 | 6.4 | 6 | 1.05 | 0.2 | 0.4 | 22.2 | 21.8 | NA | 587 | 338 | NA | 1828 | |
| 71 | M | 0 | Del(13q) | 3.7 | UM | 11.3 | 1 | PR | 14.1 | 7.5 | NA | 26.3 | 19.7 | NA | 9.18 | 0.2 | NA | 13.2 | 0 | NA | 348 | 200 | 191 | 795 | ||
| 72 | F | 0 | Del(13q) | 2.8 | MUT | 2.0 | 3 | CR | 12.6 | 15.6 | NA | 35.4 | 36.2 | NA | 4.7 | 1.2 | NA | 23 | 14.7 | NA | 191 | 170 | 156 | 387 | ||
| 73 | F | 1 | Del(17p) | 9.1 | MUT | 3.8 | 3 | Pneumonia Grade 3 | PR | 20m | 7.2 | 9.43 | NA | 19.8 | 19.0 | NA | 14.4 | 4.3 | NA | 5.9 | 2.6 | 6.4 | NA | NA | NA | 97 |
| 74 | M | 1 | Del(17p) | 4.5 | MUT | 3.8 | 4 | PR | 31m | 40.2 | 41.8 | NA | 28.4 | 19.7 | NA | 5.5 | 0.6 | NA | 38.8 | 22.9 | NA | NA | NA | NA | 849 | |
| 79 | F | 5 | Del(13q) | 4.5 | MUT | 5.6 | 4 | URI Grade 2 | PR | 43.4 | 41.2 | 41.5 | 23.8 | 25.8 | 23.4 | 88.1 | 40.2 | 40.5 | 15.1 | 5.1 | 8 | 389 | 200 | 235 | 1194 | |
| 79 | M | 3 | Neg | 3.5 | MUT | 4.4 | 3 | PR | 26.3 | NA | 29.8 | 14.9 | NA | 15 | 5.6 | NA | 19 | 12.2 | 7 | NA | NA | NA | NA | 1100 | ||
Abbreviations: B2M: β2-microglobulin; FISH, fluorescence in situ hybridization; IGHV MS, immunoglobulin heavy chain variable mutation status; 3m, after 3 months of treatment; # prior Rx, number of prior therapies; PR, partial remission; CR, complete remission; NA, not available.